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ARTICLE
A high-throughput screen indicates gemcitabine
and JAK inhibitors may be useful for treating
pediatric AML
Christina D. Drenberg1,2, Anang Shelat 3, Jinjun Dang4, Anitria Cotton4, Shelley J. Orwick2, Mengyu Li1,2,
Jae Yoon Jeon1,2, Qiang Fu1,2, Daelynn R. Buelow1,2, Marissa Pioso1,2, Shuiying Hu1,2, Hiroto Inaba4,
Raul C. Ribeiro4, Jeffrey E. Rubnitz4, Tanja A. Gruber4, R. Kiplin Guy 5 & Sharyn D. Baker1,2
Improvement in survival has been achieved for children and adolescents with AML but is
largely attributed to enhanced supportive care as opposed to the development of better
treatment regimens. High risk subtypes continue to have poor outcomes with event free
survival rates <40% despite the use of high intensity chemotherapy in combination with
hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular
accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for
pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and
cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative
to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective
for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical
models. Our approach provides advances in the development of treatment strategies for
pediatric AML.
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Dramatic improvements in survival have been achieved forchildren and adolescents with acute myeloid leukemia(AML), with 5-year survival rates increasing between
1975 and 2010 from <20% to >70%1. These improvements are
attributable to the intensification of chemotherapy, selective use
of hematopoietic stem cell transplantation, improvements in
supportive care, refinements in risk classification, and use of
minimal residual disease to monitor response to therapy2.
However, in the past decade outcome has plateaued and remain
unacceptably low for many subtypes. Provided that significant
improvements in long-term outcome are not expected with
conventional therapy alone, therapeutic strategies that can be
quickly advanced to a clinical setting are urgently needed for the
treatment of pediatric AML.
Drug discovery and development is a long process that requires
an enormous financial investment and multiple clinical trials; a
process that has an increased number of challenges and barriers
in orphan diseases such as pediatric AML. A more rational,
evidence-based approach to identify and prioritize therapeutics
advancing to clinical trials is needed. Here, we report the results
of a large-scale screen of human cancer cell lines representing two
high-risk subtypes of pediatric AML including MLL rearranged
(MLLr) with or without a co-occurring FLT3-internal tandem
duplication (FLT3-ITD) mutation and non-Down syndrome
acute megakaryoblastic leukemia (AMKL)2–4. Both FLT3-ITD
and MLLr occur in adult AML patients and are associated with
poor prognosis whereas, AMKL is extremely rare occurring in
only 1% of the adult patient population5–7. This provides a strong
rationale for identifying treatment strategies that may be unique
to pediatric AML and those that may have broader implications.
The Broad and Sanger Institutes independently reported the
results from two large-scale screens, which systematically inter-
rogated hundreds of cell lines both genetically and
pharmacologically8,9. AML represented a very small fraction of
cancer types evaluated in these studies and high-risk subtypes
including MLLr AML and non-DS AMKL were not represented
and the number of compounds evaluated were limited (Broad
study, N= 24; Sanger study, N= 130). Our current study evalu-
ates the anti-leukemic activity of nearly 8000 compounds at a
single concentration in a primary high-throughput screen (HTS)
using a panel of cell lines derived from children and young adults.
We evaluate select compounds representing a variety of drug
classes including cytotoxic and molecularly targeted agents in a
secondary dose-response HTS. To accelerate the transition of
potential therapeutics into the clinic, we prioritize hits based on
FDA-approved agents with oncology indications. Anti-leukemic
activity is validated in low-throughput assays in vitro with cell
lines, ex vivo with primary pediatric patient samples, and in vivo
using murine models. This integrated approach identifies two
FDA-approved drugs, gemcitabine and cabazitaxel, as ther-
apeutics with broad activity across multiple subtypes of pediatric
AML with dismal prognosis. In addition, we report the selective
activity of JAK inhibitors for AMKL; specifically the FDA-
approved therapeutic agent, ruxolitinib, prolongs survival in
multiple murine models of AMKL.
Results
Drug screen using AML cell lines. We validated a panel of 8
AML cell lines derived from children and young adults for
screening (Fig. 1a, Supplementary Fig. 1, Supplementary Table 1).
A primary HTS was performed using a library of 7389 com-
pounds (6568 unique) at a single concentration. Percent inhibi-
tion of cell proliferation was determined relative to the positive
control (Supplemental Data 1). Assay diagnostics were acceptable
and the scatter-plot of controls and test compound activity
demonstrated adequate separation between signal and noise for
each cell line (Supplementary Fig. 2). The range of total hits
(activity >50% inhibition) in the primary screen was 334–624 and
the number of selective hits (activity >80% in one cell line and
<20% in all others) was negligible (range 0–6; mean 2.6) (Sup-
plementary Table 2). A secondary HTS performed in a dose-
response manner, included FDA approved compounds with
inhibition >50% in more than one cell line in the primary screen,
analogs of these hits, and other compounds of interest (e.g.,
NAMPT inhibitors) not included in the primary screen; clinical
phase of testing was also taken into consideration. The average
effective concentration of each compound is reported in Fig. 1b
and Supplementary Data 2. Of the 458 compounds, we identified
17 with potency <1 µM in all cell lines; collectively, these included
histone deacetylase inhibitors (5/17), proteasome inhibitors (4/
17), PI3K inhibitor (1/17), inhibitors of anti-apoptotic proteins
(2/17), and FDA-approved cytotoxic agents (5/17) two of which
(clofarabine, mitoxantrone) are currently used in clinical regi-
mens for the treatment of AML (Table 1). We validated com-
pounds from these drug classes and others targeting pathways
known to be upregulated or mutated in MLLr or AMKL (e.g.,
trametinib, RAS pathway; alisertib, aurora kinase; RG7112,
MDM2 inhibitor)10–12 using cell lines and primary patient
samples (Fig. 2, Supplementary Fig. 3, Supplementary Table 3).
Primary patient samples were co-cultured with mesenchymal
stromal cells, which secrete multiple cytokines that mimic the
bone marrow microenvironment; this system gives support to
primary samples while challenging the drug treatment. Cell via-
bility and cell density were monitored throughout the assay
(Supplementary Fig. 4); these data demonstrate all primary
samples experience a dramatic decrease in cell number at 24 h;
though cell numbers are relatively maintained over the course of
the assay only one sample doubles from 24 to 96 h. This is an
important observation especially in regard to drugs that specifi-
cally target S phase cells and may contribute to the modest
activity of nucleoside analogues like cytarabine and gemcitabine
in this assay. We observed the HDAC inhibitors panobinostat
and romidepsin to have potent activity across subtypes; these
findings are consistent with our previous report with panobino-
stat13 and support the ongoing clinical evaluation
(NCT02676323) of this drug for pediatric AML. Similarly, the
proteasome inhibitors, carfilzomib and bortezomib, demonstrated
potent activity and have been extensively investigated in the
clinic14. Criterion for the advancement of compounds are
described in the Methods section and may permit rapid transla-
tion to a clinical trial in pediatric AML; this is essential as we
currently have access to few if any investigational agents.
Gemcitabine demonstrates potent in vitro activity. Given that
nucleoside analogs are integral to all modern AML therapy and
since gemcitabine, a nucleoside analog that is currently used to
treat advanced solid tumors in children15,16 demonstrated very
potent activity across subtypes in the secondary HTS (<65 nM);
and taken these results were validated in a low-throughput
manner (Fig. 3a) and had comparable activity to cytarabine in
primary patient samples (Fig. 2, Supplementary Table 3), we
selected this compound for further evaluation. A panel of AML
cell lines were treated with increasing concentrations of gemci-
tabine and clinically used nucleoside analogs for comparison.
Both cytarabine and fludarabine demonstrated variable activity;
whereas both clofarabine and gemcitabine had more narrow half
maximal inhibitory concentration (IC50) ranges (Fig. 3a). Overall,
gemcitabine was the most potent and had activity in cell lines that
were insensitive to cytarabine (THP-1) and fludarabine
(CHRF288-11, MV4-11).
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Collectively, nucleoside analogs share a similar mechanism of
action whereby they enter cells exclusively by transporter-
mediated processes17. Upon intracellular uptake, multiple rounds
of phosphorylation must occur before insertion into DNA18.
Reduced uptake into leukemia cells has been proposed as a
process underlying most instances of clinical resistance to
cytarabine, though the responsible mechanism remains poorly
understood19,20. To investigate whether differences in cellular
uptake were contributing to the enhanced anti-leukemic activity
of gemcitabine, we performed intracellular uptake and accumula-
tion experiments. In a comparative analysis after 5 min exposure
to cytarabine or gemcitabine, we detected a significantly greater
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Fig. 1 High-throughput screening of pediatric AML. a Illustration of the scheme used for AML cells in the screening platform. Optimal plating density was
determined per cell line in a 384-well plate; a primary screen was conducted at a single concentration and a secondary screen was performed in a dose-
response manner in triplicate. For screens, cells were plated and after 24 h compounds were pin tool transferred using an automation station. Cell viability
was measured at 72 h using Cell Titer Glo. Select compounds were validated using cell lines, primary patient samples, and/or in vivo murine models.
b Heatmap of the average effective concentration (EC50) from secondary screen. Cell lines are ordered based on a cluster analysis. Black, MLL rearranged
(MLLr); blue, FLT3-internal tandem duplication positive withMLLr; green, PICALM/MLLT10 fusion positive; red, acute megakaryoblastic leukemia. Color bar
on top of heatmap indicates compound classes: red, anti-infective and anti-psychotic; orange-red, anti-metabolite; orange, apoptosis; yellow, DNA damage;
lime, complex; green, folate, epigenetic, retinoic acid receptor; teal, Hsp90; light blue, kinase; blue, microtubule, NF-κB; purple, other; light pink,
proteasome; pink, HIF, Nrf2; NE, not evaluated
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amount (1.2–3.6-fold) of gemcitabine in all cell lines evaluated
(Fig. 3b). This observation continued over a 2-h time course and
was associated with significantly increased gemcitabine accumu-
lation (5–19.8-fold compared to cytarabine) in the nuclear
compartment (Fig. 3c, d). While the observed nuclear uptake
suggests that the active metabolite gemcitabine triphosphate
(dFdCTP) was accumulating to a much greater extent relative to
cytarabine triphosphate (Ara-CTP); these studies detect total
radioactivity, which is comprised of both active and inactive
metabolites. To determine if we were observing greater
accumulation of dFdCTP, we evaluated the accumulation of
gemcitabine monophosphate (dFdCMP), diphosphate (dFdCDP),
and dFdCTP compared to the metabolic counterparts of
cytarabine (Ara-CMP, Ara-CDP, Ara-CTP). After 2 h exposure,
significantly greater accumulation of dFdCTP compared to Ara-
CTP (7.3–61.2-fold) was observed; dFdCTP accounted for
58–81% of the total intracellular accumulation in all cell lines
evaluated whereas Ara-CTP accounted for 52–65% (Fig. 3e,
Supplementary Fig. 5a–c). Additionally, we evaluated the
accumulation using primary murine blasts isolated from the
bone marrow and spleen of treatment-naive MllPTD/wt:Flt3ITD/
ITD double knock-in primary transplants. Similarly, we observed
higher accumulation of total gemcitabine versus cytarabine
(6.0–6.7-fold) and dFdCTP versus Ara-CTP (2.4–5.3-fold) in
blasts from bone marrow or spleen (Supplementary Fig. 5d).
To determine if dose escalation could result in equivalent
intracellular exposure, we performed uptake assays at higher
concentrations of cytarabine. After 5 min exposure to cytarabine
(10 or 100 µM) we detected a significantly greater amount
(1.6–3.7-fold and 7–12-fold, respectively) compared to 1 µM
cytarabine (Fig. 3f). Furthermore, we found a 10-fold higher
concentration of cytarabine produced nearly equivalent intracel-
lular exposure to 1 µM gemcitabine. Since transporters are
biophysically complex and the interpretation of
Table 1 Compounds with EC50 < 1 µM in all cell lines evaluated in secondary HTS
Compound MOLM-13 MV4-11 CHRF288-11 CMK CMS M07e ML2 U937
Clofarabinea 0.05 0.15 0.37 0.005 0.02 0.01 0.13 0.09
Gemcitabinea 0.003 0.002 0.003 0.01 0.03 0.06 0.002 0.01
Gambogic acidc 0.19 0.17 0.22 0.36 0.26 0.24 0.15 0.19
Dactinomycind 0.03 0.04 0.001 0.001 0.04 0.001 0.001 0.001
Mitoxantronec 0.01 0.001 0.02 0.04 0.08 0.03 0.24 0.03
Trichostatin Ae 0.08 0.04 0.04 0.05 0.04 0.09 0.11 0.04
Quisinostate 0.01 0.01 0.01 0.02 0.001 0.004 0.004 0.01
CUDC-907e,k 0.0004 0.0002 0.001 0.002 0.001 0.001 0.002 0.004
Panobinostate 0.18 0.13 0.01 0.003 0.03 0.005 0.01 0.01
Romidepsine 0.001 0.001 0.01 0.01 0.001 0.002 0.004 0.003
NVP-BGT226k 0.11 0.05 0.05 0.06 0.01 0.25 0.23 0.08
Cabazitaxelm 0.001 0.0003 0.001 0.001 0.001 0.001 0.001 0.001
Ouabaino 0.03 0.04 0.04 0.18 0.05 0.06 0.03 0.04
Bortezomibp 0.002 0.002 0.002 0.01 0.001 0.001 0.001 0.02
Oprozomibp 0.01 0.01 0.03 0.01 0.001 0.01 0.01 0.01
ONX-0914p 0.07 0.05 0.17 0.23 0.11 0.08 0.04 0.13
Carfilzomibp 0.01 0.001 0.02 0.01 0.001 0.001 0.003 0.01
Mechanism of action indication as follows: a—anti-metabolite; c—complex; d—DNA; e—epigenetic; k—kinase; m—mitotic; o—other; p—proteasome
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Fig. 2 Activity of compounds in primary AML blast samples. Primary blast samples from patients harboring a MLL rearrangement (MLLr), FLT3-internal
tandem duplication positive (FLT3-ITD+), or with acute megakaryoblastic leukemia (AMKL) were plated on mesenchymal stromal cells and treated with
DMSO or increasing concentrations of indicated compounds. Cell viability was determined at 96 h using Cell Titer Glo. The half maximal inhibitory
concentration (IC50) was evaluated by nonlinear regression analysis using GraphPad Prism (N= 3 per concentration). Heatmap indicates IC50
concentration for each compound per patient sample
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09917-0
4 NATURE COMMUNICATIONS |         (2019) 10:2189 | https://doi.org/10.1038/s41467-019-09917-0 | www.nature.com/naturecommunications
Michaelis–Menten parameters with regard to underlying trans-
porter dynamics can be difficult21–23, we evaluated transporter
kinetics by calculating the transport efficiency for these
compounds to gain a greater mechanistic understanding of these
data. Overall transport efficiency of gemcitabine was significantly
greater compared to cytarabine and this could not be overcome
with increasing concentrations (Fig. 3g).
Given that previous investigations demonstrated that low
cytarabine uptake in AML cells predicts poor response to
therapy17 and taken our data showing uptake and transport
efficiency as a major contributor to the enhanced sensitivity of
AML cells to gemcitabine we performed knockdown experiments
targeting two key transporters involved in nucleoside uptake
OCTN1 and ENT120,24. Using siRNA we were able to achieve a
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54% and 41% reduction in expression of OCTN1 and ENT1,
respectively (Fig. 3h). At 24 h post-transfection, cells were treated
with PBS, gemcitabine, or cytarabine then alterations in their
cytotoxicity profile were assessed using perturbations in cell cycle
as the read-out. Inhibition of both transporters resulted in a
decrease of cytarabine- and gemcitabine-mediated accumulation
of cells in S-phase; the effect was greater with gemcitabine in
ENT1 deficient cells and comparable in both OCTN1 and ENT1
deficient cells with cytarabine (Fig. 3i).
Taxanes demonstrate potent in vitro activity. Another class of
cytotoxic agents demonstrating potent activity across subtypes
were microtubule poisons, specifically taxanes. Cabazitaxel
demonstrated potent single agent activity in the secondary HTS
and primary patient samples (Figs. 1b and 2, Table 1); likewise,
docetaxel demonstrated potent activity in all but one cell line
(Supplementary Data 2). These results are consistent with a
recent report showing that primary AML cells were sensitive to
docetaxel when drug sensitivity and resistance testing was per-
formed in the presence of HS-5 human bone marrow stromal cell
conditioned media25. We validated the results from the HTS and
found cabazitaxel, docetaxel, and paclitaxel have potent activity in
a panel of AML cell lines (Fig. 4a); cabazitaxel was the most
potent so we selected this compound for further evaluation.
Microtubule poisons like taxanes interfere with the faithful
segregation of chromosomes by binding tubulin and disrupting
the mitotic spindle causing a G2/M cell cycle arrest, leading to
mitotic catastrophe, and ultimately resulting in cell death26.
Therefore, we assessed the mechanism by which cabazitaxel
triggers cell death in AML cells by analyzing cell cycle
perturbations and using a biparametric approach of markers
associated with mitosis. A time-course analysis showed that cell
cycle blockage was detected prior to cell death: G2/M arrest was
detectable at 4 h and more prominent at 8 and 12 h, whereas cell
death was detectable at 12 h and more pronounced at 24 h
(Fig. 4b, Supplementary Fig. 6). The G2/M arrest was accom-
panied by a significant induction of cyclin B and phosphorylation
of histone H3 (Fig. 4c). These results suggest that cabazitaxel
induces a mitotic arrest in AML cells, which leads to cell death.
Establishment of AMKL murine models. Development and
implementation of preclinical in vivo models that faithfully
recapitulate human disease are imperative to enhance the pre-
dictive power of potential therapeutics. In an effort to establish
murine models for AMKL, we labeled CHRF288-11 cells with
YFP/luciferase (CHRF288-11-Luc+) to permit monitoring
engraftment through bioluminescence imaging; we found
CHRF288-11-Luc+ cells could engraft in both female and male
mice (Supplementary Fig. 7). We have previously identified a
pediatric-specific rearrangement yielding a CBFA2T3/GLIS2
fusion which is associated with aberrant JAK/STAT signaling and
often co-occurs with mutations in JAK kinase family members,
STAT genes, or the thrombopoietin receptorMPL27; patients with
this lesion show the strongest negative association with survival
and highest cumulative incidence of relapse or primary resis-
tance28. While expression of this gene fusion results in increased
self-renewal, transplantation of fusion gene-modified bone mar-
row cells fails to induce leukemia suggesting there is an essential
requirement for cooperating mutation(s) in cases expressing the
gene fusion29,30. We evaluated the transforming potential of dual
expression of CBFA2T3-GLIS2 with a clinically relevant
JAK2V617F cooperating mutation (CG/V617); concurrent
expression uniformly induced a rapid and fatal leukemia char-
acteristic of AMKL and transplantable into subsequent recipients
(Supplementary Fig. 8). We then incorporated luciferase into CG/
V617 AMKL blasts isolated from secondary transplants (CG/
V617-Luc+). The bioluminescence signal could be detected in the
hind limbs 15 days earlier than CG/V617 cells in the peripheral
blood and CG/V617-Luc+ transplants exhibited a highly pene-
trant phenotypically similar AMKL to the CG/V617 transplants
(Supplementary Fig. 8e). We also established a patient-derived
xenograft (PDX) using a sample from a pediatric patient with
AMKL that was previously identified to carry the CBFA2T3-
GLIS2 fusion plus copy number alterations and amplification on
chromosome 21, a major cooperating event that includes genes in
the Down Syndrome critical region27. These models replicate
many features of human AMKL and provide a robust tool set for
preclinical evaluation of therapeutic strategies.
Gemcitabine and cabazitaxel prolong in vivo survival. Next, we
sought to compare the in vivo efficacy of gemcitabine and
cabazitaxel to the standard of care, cytarabine. Due to limitations
with tolerability, we have previously treated our AML xenograft
models with low-dose cytarabine13,31. This regimen did not
provide any survival advantage compared to vehicle treated mice
(median survival 26 versus 26 days) in the CHRF288-11-Luc+
model (Supplementary Fig. 9). Tolerability studies of gemcitabine
at the same dose and schedule was not tolerated. Therefore, we
performed tolerability using multiple doses on an intermittent
every 3 or 4-day schedule; all regimens of gemcitabine were well
tolerated. Similarly, we performed tolerability of cabazitaxel using
multiple doses on an intermittent every 3 or 4-day schedule; the
only tolerable dose was 5 mg/kg.
For efficacy studies performed using immunocompromised
mice, we found cytarabine did not provide any survival advantage
compared to vehicle treated mice in cell line xenografts; whereas
in the AMKL PDX cytarabine significantly prolonged survival
(log-rank test, P= 0.0023) (Fig. 5, Supplementary Figs. 10–11). In
the AMKL xenograft models, gemcitabine provided the greatest
survival advantage and significantly prolonged survival versus
cytarabine after one (log-rank test, P= 0.0023) or two treatment
cycles (log-rank test; CHRF288-11-Luc+, P= 0.0019; AMKL
PDX, P= 0.0026). Treatment with gemcitabine significantly
inhibited tumor burden compared to cytarabine as indicated by
a reduced bioluminescence signal and decreased infiltration in the
peripheral blood. While cabazitaxel significantly prolonged
survival versus cytarabine after one (log-rank test, P= 0.0023)
or two cycles (log-rank test, P= 0.0023) in the CHRF288-11-Luc
+ xenograft, we did not observe a significant difference in the
AMKL PDX (Fig. 5, Supplementary Fig. 10). Surprisingly, we
found the additional treatment cycle of cabazitaxel in the
CHRF288-11-Luc+ model did not further prolong survival
compared to one cycle. Although gemcitabine significantly
prolonged survival versus cytarabine in the ML-2 xenograft
model (log-rank test, P= 0.0027); cabazitaxel provided the
greatest survival advantage (log-rank test, P= 0.0027) and
significantly inhibited tumor burden compared to cytarabine
(Fig. 5c, Supplementary Fig. 11).
Next, we sought to evaluate efficacy in two syngeneic murine
models using a maximum tolerated dose (MTD) of cytarabine
that better reflects clinical regimens. Tolerability of gemcitabine
was performed using multiple doses on an intermittent or daily
schedule (Supplementary Fig. 12) to establish the MTD. For
efficacy studies in CG-V617-Luc+ quaternary transplants, mice
were treated with gemcitabine (MTD daily or intermittent) or
cytarabine (daily). We found both dosing regimens of cytarabine
provided a survival advantage compared to vehicle treated mice
(log-rank test, P= 0.0091) (Fig. 5d). However, gemcitabine
provided the greatest survival advantage (log-rank test, daily,
P= 0.0091; intermittent, P= 0.004) and significantly prolonged
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Fig. 4 Activity of taxanes in AML cell lines. a AML cells were treated with increasing concentrations of vehicle or taxane (cabazitaxel, Cab; docetaxel, Doce;
paclitaxel, Pac) for 72 h, and cell viability was measured using Cell Titer Glo. Data are reported as percent control and represented as mean ± standard
deviation (SD) of 3 independent experiments (N= 18 per concentration). The half maximal inhibitory concentration (IC50) was evaluated by nonlinear
regression analysis using GraphPad Prism. CHRF288-11, ML-2, and MOLM-13 cells were treated with 5 or 50 nM Cab or DMSO for 12 h; b cell cycle
distribution was determined by DAPI staining and c induction of mitosis was determined by biparametric flow cytometry using p-histone H3 and cyclin B1.
Data are mean ± standard deviation from 3 independent experiments (N= 3); Student’s t test. *P < 0.01; **P < 0.001; ***P < 0.0001
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survival versus cytarabine (log-rank test, P= 0.0027). Treatment
with gemcitabine significantly inhibited tumor burden compared
to cytarabine as indicated by decreased infiltration in the
peripheral blood (Fig. 5d).
Lastly, we evaluated efficacy using a MllPTD/wt:Flt3ITD/ITD
double knock-in murine model32,33. Primary transplants were
treated with intermittent dosing of gemcitabine, cytarabine, or
cabazitaxel; whereas, secondary transplants were treated with
MTD of gemcitabine (daily or intermittent) or cytarabine (daily).
In primary transplants, cytarabine did not significantly prolong
survival compared with vehicle; whereas transplants treated with
cabazitaxel (log-rank test, P= 0.011) achieved a significant
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survival advantage (Fig. 5e, Supplementary Fig. 13). Gemcitabine
provided the greatest survival advantage and significantly
prolonged survival compared to all other treatment regimens
(log-rank test; versus vehicle, P= 0.0013; versus cytarabine, P=
0.024; versus cabazitaxel, P= 0.007). In secondary transplants,
cytarabine significantly prolonged survival compared with vehicle
(log-rank test, P= 0.009); similarly daily MTD of gemcitabine
significantly prolonged survival compared with vehicle (log-rank
test, P= 0.009) (Fig. 5f). The intermittent MTD of gemcitabine
was not well tolerated and mice only received 4 doses on this
regimen (Supplementary Fig. 15); we attribute the lack of
tolerability to the short time frame between treatment initiation
and irradiation prior to transplant. Interestingly, however,
weights fully recovered and mice had a profound response to
the limited regimen achieving a significant survival advantage
compared to vehicle (log-rank test, P= 0.0006) (Fig. 5f). All
treatment groups had a significant reduction in tumor burden
compared to vehicle on day 13 as indicated by decreased
infiltration in the peripheral blood.
JAK inhibitors are selective for AMKL. In addition to identi-
fying compounds with broad activity across high-risk subtypes,
we also wanted to identify leads that were selective for specific
subtypes or genetic abnormalities. Regarding the former, we
found JAK inhibitors demonstrate potent selective activity for
AMKL versus other subtypes and confirmed these findings
(Supplementary Data 2, Supplementary Fig. 15). Due to the
potential for clinical translation we prioritized evaluation of the
two currently FDA-approved inhibitors (ruxolitinib, tofacitinib).
Using an expanded panel of AMKL cells lines (N= 9), we found
ruxolitinib to have more potent activity compared to tofacitinib
(Fig. 6a). Interestingly, both compounds were not active in the
two AMKL cell lines (Meg-01, MKPL) established from adult
patients. We evaluated ruxolitinib sensitivity using primary blasts
isolated from treatment naive CG/V617 tertiary transplants; we
observed the primary murine blasts to be sensitive to ruxolitinib
(Supplementary Fig. 16). These findings are consistent with the
role JAK/STAT signaling plays in the underlying biology driving
megakaryopoiesis and recurrent genetic aberrations in a sig-
nificant portion of AMKL cases that result in upregulated JAK/
STAT signaling27,30. To gain insight into the activity underlying
the enhanced potency of ruxolitinib, we compared the binding
affinity and kinase inhibition of JAK family members. In a
binding assay, ruxolitinib has the highest affinity to the catalytic
domain of JAK2 whereas tofacitinib demonstrated highest bind-
ing affinity for the catalytic domain of JAK3 (Table 2). In a kinase
assay, ruxolitinib potently (IC50 < 1 nM) inhibited the enzymatic
activity of JAK1, JAK2, and TYK2; in contrast tofacitinib potently
inhibited JAK3 (Table 2). These findings are in agreement with
the reported selectivity of both inhibitors34,35.
Next, we compared the expression levels of JAK-STAT family
members among a panel of AMKL (JAK mutated: CHRF288-11,
CMK, CMY; CBFA2T3-GLIS2 positive: CMS, M07e, M-MOK,
WSU) and non-AMKL (MLLr: ML-2; MLLr with FLT3-ITD:
MOLM-13, MV4-11; other: U937) cell lines using RNA-seq data
to provide insight into the mechanism driving subtype selective
activity. We found multiple JAK-STAT family members includ-
ing JAK1 (2-fold), JAK3 (9.3-fold), STAT3 (3.5-fold), STAT5A
(6-fold), STAT5B (2.9-fold) were significantly increased in AMKL
compared to non-AMKL cell lines (Fig. 6b). We validated our
findings using an expanded panel of AML cell lines and
confirmed STAT5A expression is significantly higher at both
the RNA and protein level in AMKL compared to non-AMKL,
with the exception of HEL cells (positive control) that harbor a
JAK2V617F mutation (Fig. 6c, e). Furthermore, we determined
there is a high and significant correlation between STAT5A
expression and ruxolitinib sensitivity in the AMKL cell lines
(Fig. 6d); the sensitivity to ruxolitinib was also associated with a
reduction in p-STAT5A signaling in AMKL regardless of JAK
mutation status (Fig. 6e, f). Previous investigations have shown
JAK signaling can be stimulated by a variety of cytokines/
chemokines including BMP236, erythropoietin (EPO)37, and
thrombopoietin (TPO)38,39. Since TPO plays a primary role
and EPO, to a lesser extent, in the maintenance of megakar-
yocytes, and given our previous report showing elevated BMP2
expression in CBFA2T3-GLIS2-positive AMKL patients27 we
determined if co-exposure would affect ruxolitinib sensitivity. We
performed a cell viability assay using increasing concentrations of
ruxolitinib with or without BMP2, EPO, or TPO. We found that
TPO, a glycoprotein critical to megakaryocyte differentiation,
caused a rightward shift of the dose-response curve resulting in a
higher IC50 concentration, an indication of resistance (Fig. 6g).
The observed resistance correlated with an induction of
p-STAT5A signaling following stimulation with TPO (Fig. 6h).
Pharmacological assessment of ruxolitinib. Next, we deter-
mined the pharmacokinetic properties of ruxolitinib following
oral administration in the two mouse strains used for efficacy
studies. A single dose of ruxolitinib was administered and total
ruxolitinib concentrations in plasma were measured over a 2 h
time-course. Concentration-time profiles and a summary of
ruxolitinib pharmacokinetic parameters are shown in Fig. 7a, b
and Supplementary Table 4. Although we observed strain dif-
ferences, overall the area under the curve values and half-life
approach those observed clinically in children with relapsed
cancers40.
Ruxolitinib prolongs in vivo survival in multiple models.
Finally, we evaluated the in vivo efficacy of ruxolitinib using
multiple murine models of AMKL. We found that ruxolitinib
significantly prolonged survival compared to vehicle in all three
models (log-rank test; CHRF288-11-Luc+, P= 0.003; CG-V617-
Luc+ quaternary transplants, P= 0.004; AMKL PDX, P= 0.005)
and significantly inhibited tumor burden compared to vehicle as
indicated by a reduced bioluminescence and decreased infiltration
in the peripheral blood (Fig. 7c–e).
Fig. 5 In vivo activity of gemcitabine and cabazitaxel. Kaplan–Meier analysis (top panels) of animal survival in a CHRF288-11-luciferase/YFP+ xenograft,
b AMKL patient-derived xenograft, c ML-2-luciferase/YFP+ xenograft, d CBFA2T3-GLIS2/JAK2V617F-induced AMKL model, and e, f MLL-PTD/wt:FLT3ITD/
ITD-double knock-in model. a–c, e Mice were randomized to receive vehicle (black), 50mg kg−1 cytarabine (Ara-C, blue), gemcitabine 50mg kg−1 (Gem,
magenta), or cabazitaxel 5 mg kg−1 (Cab, gray) once every 4 days (q4d) for 3 weeks for up to 2 cycles; or d, f mice were randomized to receive vehicle
(black), 50mg kg−1 cytarabine (Ara-C, blue, solid line), 100mg kg−1 cytarabine (Ara-C, blue, dashed line), or gemcitabine 3 mg kg−1 (Gem, magenta, solid
line) once daily for 5 days for up to 3 cycles or 120mg kg−1 gemcitabine (Gem, magenta, dashed line) once every 3 days (q3d) for 3 weeks for up to 1.5
cycles. All treatments were administered by intraperitoneal injection, black arrows indicate treatment schedule per model. Tumor burden was monitored
(bottom panels) by a, c bioluminescent imaging, b detection of human CD45+ cells in peripheral blood, d detection of GFP/mCherry double positive (DP)
cells in peripheral blood, or e, f detection of Ly5.2+ cells in peripheral blood. Student’s t test; NS not significant; *P < 0.05; **P < 0.01; ***P < 0.0001
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Discussion
Despite many advances in the treatment of pediatric AML, the
long-term survival is still unacceptably low and new therapeutic
strategies are urgently needed for patients with high-risk sub-
types. Using an integrated approach we have identified alternative
chemotherapeutic regimens can be superior to standard of care
and targeted agents may be useful for select subtypes. Collectively,
our data suggest that treatment success could be improved
through a repurposing strategy.
Nucleoside analogs have been widely used in the treatment of
hematologic malignancies of which cytarabine is the mainstay of
therapy in AML41. Cytarabine and gemcitabine are structurally
similar nucleoside analogs that require cellular uptake and acti-
vation through multiple intracellular phosphorylation steps.
While both drugs are activated by the same enzymes, gemcitabine
has additional mechanisms of action and a pattern of self-
potentiation that is unique among nucleoside analogs42,43. Due to
its higher affinity for deoxycytidine kinase gemcitabine undergoes
greater activation to mono- and di-phosphorylated metabolites
compared to cytarabine and fludarabine43,44. Further, dFdCDP
is reported to inhibit ribonucleotide reductase, an enzyme in
the nucleotide pathway and critical for management of
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Fig. 6 Activity of JAK inhibitors for AMKL. a AMKL cells were treated with increasing concentrations of vehicle or JAK inhibitor (tofacitinib, ruxolitinib) for
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analysis using GraphPad Prism. b Expression of JAK-STAT family members was determined by RNAseq in AMKL cell lines (blue; CHRF288-11, CMK, CMS,
CMY, M-MOK, M07e, WSU; N= 7) compared to non-AMKL cell lines (black; ML-2, MOLM-13, MV4–11, U937; N= 4). Data are mean ± standard
deviation (SD). c Confirmation of STAT5A expression using a TaqMan expression assay was performed in an expanded panel of AML cell lines (blue circle,
AMKL; magenta circle, HEL; black, non-AMKL) and normalized to GAPDH (left). Data are mean ± SD (N= 6). Mean per group ± SD (right). d Correlation
analysis of STAT5A expression and ruxolitinib (Rux) IC50 in AMKL cell lines was determined by Pearson correlation and linear regression. e Protein
expression of total STAT5 (t-STAT5) in a panel of AMKL and non-AMKL cell lines. f AMKL cell lines (CHRF288-11, M07e) were exposed to their
respective ruxolitinib IC50 (143 and 45 nM) for 1 h then lysed. Western blot analysis was performed on whole cell lysate to evaluate protein expression of
phospho-STAT5 (p-STAT5) and t-STAT5; GAPDH was used as a loading control. g CHRF288-11 cells were treated with increasing concentrations of
ruxolitinib (magenta) with or without 100 ngmL−1 of BMP2 (black), EPO (blue), or TPO (gray) for 72 h and cell viability was measured using Cell Titer Glo.
Data are reported as percent control and represented as mean ± SD of 3 independent experiments (N= 18 per concentration). The IC50 (dotted line) was
evaluated by nonlinear regression analysis using GraphPad Prism. h CHRF288-11 cells were treated with 100 ngmL−1 of TPO for up to 1 h and lysed;
western blot analysis was performed on whole cell lysate to evaluate protein expression of p-STAT5 and t-STAT5; GAPDH was used as a loading control.
Student’s t test; **P < 0.01; ***P < 0.0001
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Table 2 Ruxolitinib and tofacitinib in vitro kinase binding and inhibition
Target in binding assaya Kd Ruxolitinib (nM) Kd Tofacitinib (nM) Target in kinase assay IC50 Ruxolitinib (nM) IC50 Tofacitinib (nM)
JAK1 H1 domain-catalytic 11 5.2 JAK1 0.54 1.9
JAK1 JH2 domain-
pseudokinase
15,000 30,000 JAK2 0.47 6.2
JAK2 JH1 domain-catalytic 0.054 0.59 JAK2V617F 1.5 2.4
JAK3 JH1 domain-catalytic 0.87 0.18 JAK3 14.7 0.97
TYK2 JH1 domain-catalytic 0.25 6.4 TYK2 0.45 25
TYK2 JH2 domain-
pseudokinase
2200 30,000
aData obtained from KdELECT
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Fig. 7 Pharmacokinetics and in vivo activity of ruxolitinib. Pharmacokinetic profile in female (magenta) and male (blue) a NSG and b BoyJ mice treated with
a single dose of ruxolitinib (60mg kg−1, oral gavage). Serial blood sampling was performed and ruxolitinib plasma concentrations were determined by LC-
MS/MS. Data are mean ± standard error (SE) (N= 5 per gender). Concentration-time data were analyzed by non-compartmental analysis and
pharmacokinetic parameters were calculated in WinNonLin. c–e, top Kaplan–Meier analysis of animal survival in c CHRF288–11-luciferase/YFP+ xenograft,
d CBFA2T3-GLIS2/JAK2V617F-induced AMKL quaternary transplants, and e AMKL patient-derived xenograft. Mice were randomized to receive vehicle
(black) or ruxolitinib (blue; 60mg kg−1) twice daily for 5 days for up to 4 weeks; black arrows indicate treatment schedule per model. c–e, bottom Tumor
burden was monitored by c, d bioluminescent imaging or e detection of human CD45+ cells in peripheral blood; data are mean ± SE. Student’s t test; *P <
0.01; **P < 0.0001
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deoxynucleotide pools in cancer cells45. Incorporation of dFdCTP
into DNA results in masked chain termination, where one
additional deoxynucleotide is incorporated before termination of
DNA synthesis. This specific type of nucleotide linkage masks the
gemcitabine nucleotide and prevents recognition by exonuclease
making repair difficult44,46. These mechanisms are likely con-
tributing to the significantly greater anti-leukemic activity of
gemcitabine that we observed.
Besides inherent mechanisms of action we attribute the
enhanced activity of gemcitabine to mechanisms of drug uptake
and efflux, processes that contribute to intracellular accumula-
tion. This is supported by our observations demonstrating a
significantly greater accumulation of gemcitabine and metabo-
lites. Our observation that the rate of accumulation of dFdCTP
was linear up to 2 h is consistent with the results of Gandhi and
Plunkett, who found accumulation of gemcitabine to be linear up
to 3 h in K562 cells47. Together the rate of drug uptake, efficiency
of phosphorylation, and efflux influence the rate of triphosphate
formation and cellular retention for both cytarabine and gemci-
tabine which ultimately impacts cytotoxicity. We performed
uptake assays at increased concentrations of cytarabine and
demonstrated that a 10-fold higher was necessary to achieve
similar intracellular exposure compared to gemcitabine. These
results are consistent with a previous report by Hertel et al.48,
which demonstrated a minimum effective concentration of
cytarabine is 10-fold higher than gemcitabine in CCRF-CEM cells
(T lymphoblastoid cell line) and our own data showing a higher
IC50 for cytarabine compared to gemcitabine. Here, we show the
transport efficiency of both drugs and demonstrate that even at
escalated concentrations of cytarabine, AML cells have the
capacity to transport gemcitabine more efficiently which con-
tributes to the observed differences in intracellular accumulation
and cytotoxicity.
While the human ENT1 is thought to be the primary trans-
porter mediating drug influx, we recently identified that entry of
cytarabine and several structurally related nucleosides, including
gemcitabine, is facilitated by the ergothioneine uptake transporter
OCTN1 (SLC22A4; ETT); and low expression of OCTN1 in
leukemia cells is a strong predictor of poor survival in multiple
cohorts of patients with AML treated with cytarabine-based
regimens20. In a parallel study, we reported that cytarabine and
Ara-CMP are sensitive to multi-drug resistant protein 4 (MRP4)-
mediated efflux, thereby decreasing its cytotoxic response against
AML blasts49. In contrast, a similar study found that gemcitabine
and its metabolites are not effluxed by MRP4 or MRP550. It can
thus be postulated that differential expression and activity of
uptake transporters and their affinities for nucleoside analogs,
phosphorylating enzymes that result in active metabolites, and
MRPs that mediate drug efflux, play a crucial role in the differ-
ential anti-leukemic activity of these compounds. This is con-
sistent with our previous report showing over-expression of
OCTN1 in HEK293 cells resulted in increased sensitivity to
multiple nucleoside analogs, including cytarabine20 and our
current findings that inhibition of OCTN1 and ENT1 reduced the
accumulation of AML cells in S-phase with gemcitabine or
cytarabine treatment.
A phase II study of gemcitabine as a single agent demonstrated
no significant activity in relapsed and refractory childhood acute
leukemias51. However, these results were not anticipated and the
lack of activity was unclear though patients were heavily pre-
treated and gemcitabine was administered as a continuous 360
min infusion rather than a more contemporary intermittent
schedule with a 30 min to 1 h infusion.
Our preclinical studies suggest that cabazitaxel triggers a
mitotic cell cycle arrest which leads to cell death and can sig-
nificantly prolong survival in multiple murine models of AML.
Though pre-clinical studies have shown that paclitaxel and doc-
etaxel were efficient in killing pediatric solid tumors and acute
leukemia, tubulin-stabilizing agents have undergone limited
clinical testing in pediatric oncology52,53. There is evidence for
taxanes exhibiting synergistic toxicity when combined with other
cytotoxic agents such as cisplatin in highly resistant brain
tumors52. It has been suggested that limited success with taxanes
may be attributed, in part, to early phase trials conducted in
heavily pre-treated patients52,54. More recently, results from the
NCT01751308 clinical trial evaluated the safety and efficacy of
cabazitaxel in pediatric patients with refractory solid tumors.
Although no objective responses were observed in the phase I
dose-escalation portion of the trial, a MTD was established in this
pediatric population. The lack of neurotoxicity in this clinical trial
is of potential relevance in regard to safety concerns of taxanes in
children and allowing for potential clinical translation in a high-
risk and/or relapsed/refractory setting.
In this study, we also observed multiple kinase inhibitors tar-
geting a variety of kinases involved in mitosis including alisertib
(aurora A; active 4/8), barasertib (aurora B; active 3/8), MK-1775
(Wee1; active 7/8) rigosertib (polo-like kinase; active 7/8), and
volasertib (polo-like kinase; active 7/8) and motor protein inhi-
bitor ARRY-520 (Eg5; active 3/8) to have anti-leukemic activity,
highlighting a vulnerability inherent to AML, among other can-
cers (Supplementary Data 2). Several of these compounds are in
late stage clinical development, specifically polo-like kinase 1
inhibitors, which demonstrated broad activity in both our HTS
and in primary patient samples and have been recognized as
Innovative Therapy in Leukemia by the FDA; volasertib has been
designated an orphan drug and received breakthrough therapy
status for the treatment of AML by the FDA55,56. However, a
primary analysis of a phase III study for the treatment of AML
with volasertib plus low-dose cytarabine (LDAC) versus placebo
plus LDAC did not meet the primary endpoint and patients
receiving volasertib plus LDAC were at higher risk for fatal
infections57. Therefore, further work will be required to refine our
understanding of cell cycle regulation and aberrant function of
key regulators that may have a broad role in leukemogenesis or
that may associate with specific subtypes and may guide our
selection of the optimal mitotic-targeted agent for the treatment
of AML.
The clinically used JAK inhibitor ruxolitinib demonstrated
selective activity for AMKL and had slightly greater activity
compared to tofacitinib. Interestingly, we found a significantly
higher expression of STAT5A in AMKL compared to non-AMKL
cell lines, including those with FLT3-ITD; and expression highly
correlated with ruxolitinib sensitivity compared to other JAK-
STAT family members. Our findings suggest that targeting
STAT5A is integral to the underlying mechanism driving rux-
olitinib’s selective activity in AMKL. While ruxolitinib has been
approved for intermediate to high-risk myelofibrosis, the Chil-
dren’s Oncology Group has completed a phase 1 study in relapse/
refractory solid tumors, leukemia, and myeloproliferative neo-
plasms where a tolerable pediatric dose and schedule was estab-
lished40; current clinical trials are evaluating ruxolitinib in
combination with chemotherapy for the treatment of pediatric
lymphoblastic leukemia (NTC02723994).
Collectively, these data provide a rationale for the evaluation of
gemcitabine and cabazitaxel in pediatric AML. These agents
demonstrated broad activity across multiple high-risk subtypes
and may exhibit therapeutic benefit in other subtypes of child-
hood AML. Similarly, our data provide justification for the clin-
ical evaluation of ruxolitinib for the treatment of pediatric AMKL.
Further evaluation regarding optimal dose and schedule in
addition to the identification of drug combinations will inform
future clinical trial design.
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Methods
Cell culture and reagents. Human AML cell lines HEL 92.1.7 (HEL; ATCC TIB-
180), HL-60 (ATCC CCL-240), Meg-01 (ATCC CRL-2021), MV4-11 (ATCC CRL-
9591), THP-1 (ATCC TIB-202), and U937 (ATCC CRL-1593.2) cells were
obtained from ATCC (Manassas, VA); ML-2 (ACC-15), M07e (ACC-104),
MOLM-13 (ACC-554), NB4 (ACC-207), and PL-21 (ACC-536) cells were obtained
from DSMZ (Braunschweig, Germany); MKPL-1 (MKPL; JCRB1325) cell were
obtained from Japanese Collection of Research Bioresources Cell Bank (Osaka,
Japan); M-MOK (RCB2534) cells were obtained from RIKEN BioResource
Research Center (Tsukuba, Japan); WSU-AML cells were obtained from Asterand
Bioscience (Hicksville, NY); CHRF288-11 cells were a kind gift from Dr. Tanja
Gruber (St. Jude Children’s Research Hospital [SJCRH], Memphis, TN); CMK,
CMS, and CMY cells were a kind gift from Dr. Jeffrey Taub (Karmanos Cancer
Center Institute, Detroit, MI); OCI-AML3 were a kind gift from Dr. Brian Sor-
rentino (SJCRH). Note, the U937 cell line has been listed in the database of
commonly misidentified cell lines; this cell line has been used in this report as a
representation of a more mature pro-monocytic leukemia, authentication was
confirmed prior to use. All cell lines are tested regularly for mycoplasma con-
tamination using a commercially available kit (Lonza, Walkersville, MD) and
verified by STR profile. Passages are kept to a minimum and cells are not used
beyond passage 30. Cells were cultured in RPMI1640 media with L-glutamine (Life
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals, Lawrenceville, GA) at 37 °C in a humidified incubator with 5%
CO2. M07e cells were supplemented with 10 ng/mL IL-3 (Life Technologies); M-
MOK cells were supplemented with 10 ng/mL GM-CSF (Life Technologies); MKPL
cells were supplemented with 20% FBS. Primary AML blasts from 10 patients with
FLT3-ITD (N= 3), MLLr leukemia (t(6;11); N= 6), or AMKL (N= 2) were
obtained with patient or parent/guardian-provided informed consent under pro-
tocols approved by the Institutional Review Board at SJCRH. Mesenchymal stromal
cells (MSC) were obtained from Dr. Dario Campana and cultured in RPMI1640
with L-glutamine and supplemented with 10% FBS and 1 µM hydrocortisone
(complete MSC media) (Sigma-Aldrich, St. Louis, MO).
For low-throughput in vitro studies, artesunate, cytarabine, and docetaxel were
purchased from Sigma-Aldrich; gemcitabine, cabazitaxel, paclitaxel, panobinostat,
vorinostat, ABT-199, bortezomib, carfilzomib, GDC-0941, ibrutinib, trametinib,
and sorafenib were purchased from LC Labs (Woburn, MA); romidepsin, RG7112,
BMN673, MK-1775, volasertib, alisertib, palbociclib, clofarabine, and fludarabine
were purchased from Selleck Chemicals (Houston, TX). All compounds were
prepared in DMSO, except nucleoside analogs which were prepared in phosphate
buffered saline (PBS).
High-throughput screen. Prior to screening, the optimal growth conditions
including plating density and DMSO-sensitivity for all cell lines were determined.
Briefly, for primary screening, cells were seeded in 25 µL culture medium in each
well of 384-well plates (Corning, Tewksbury, MA) using an automated plate filler
(Wellmate, ThermoFisher Scientific, Waltham, MA). After 24 h, 25 nL of solution
containing a panel of compounds (N= 7389) were pin transferred into 384-well
plates resulting in approximately 10 µM final drug concentration. Each plate
included DMSO only negative controls and cyclohexamide single point (0.5 µM)
and dose-response (0.01 nM to 0.5 µM) positive controls. Cell viability was
determined using Cell Titer Glo (CTG; Promega, Madison, WI) and an automated
Envision plate reader (Perkin-Elmer, Waltham, MA) after a 72-h incubation.
Luminescence data were normalized by log10 transformation and the percentage
inhibition= 100 × (sample result− negative control mean)/(positive control mean
− negative control mean) calculated. Similarly, secondary screens were conducted
in a dose-response manner (10-point curve, 1 nM to 10 µM); a limited number of
compounds (N= 458) were applied in serial dilution (0.5 nM to 10 µM final
concentration) and repeated in triplicate. Compounds selection for the secondary
screen was based on the following: (1) demonstration of >50% inhibition in more
than one cell line in the primary screen; (2) currently or previously evaluated in
clinical phase testing; (3) analogs of compounds in the primary screen showing
activity that were not included; (4) compound classes of interest not included in
primary screen. For dose-response drugging, each compound is drugged against
multiple wells per plate at different concentrations per well. After a 72-h incuba-
tion, cell viability was determined by the CTG/EnVision system. Dose-response
curves were fit using the drc package in R. The four parameters sigmoidal function
LL2.4 was used with the following constraints: −10 ≤ hill slope ≤ 0; 0 ≤ y0 ≤max
median normalized % activity; 0 ≤ yFin ≤max median normalized % activity;
1010 ≤ ec50 ≤ 10–4 (which equates to the range of drug concentrations tested in this
experiment). Values from the highest concentrations tested for each compound are
weighted at 10% to reduce curve fitting artifacts. In the event of a failure to fit a
sigmoidal dose-response curve, the smooth.spline option in R was used to fit a curve
that could be used to determine the area under the curve.
We used the following criteria for the advancement of compounds from the
secondary screen that demonstrated broad activity across subtypes (e.g., EC50 < 1
µM in all cell lines, listed in Table 1): (1) the drug is FDA-approved, (2) a pediatric
dose has been determined or the agent is in phase 1 pediatric testing, and (3) the
drug is not currently used clinically or under investigation for the treatment of
adult or pediatric AML.
Cell viability assays. Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich) or Cell Titer
Glo (Promega) in a low-throughput manner. Cell lines were seeded in 96-well
plates and treated with increasing concentrations of drug for 72 h. Three inde-
pendent experiments were performed (18 total replicates per concentration). At 68
h after treatment, 10 μL of MTT reagent (5 mg/mL MTT in PBS) was added to each
well and plates were incubated at 37 °C with 5% CO2 for 4 h; formazan crystals
were solubilized with 100 μL of acidified isopropanol (Sigma-Aldrich). Cell Titer
Glo was used according to the manufacturer’s instructions. The absorbance or
luminescence was measured using a Synergy H4 (Biotek Instruments, Inc.,
Winooski, VT). The half maximal inhibitory concentration (IC50) was evaluated by
nonlinear regression analysis in the software program GraphPad Prism version
5.04 (GraphPad Software, La Jolla, CA).
Ex vivo drug treatments with primary AML blast samples. Bone marrow MSCs
were plated in 96-well plates at a density of 10,000 cells/well in complete MSC
media. After 48 h, complete MSC media was removed and replaced by RPMI1640
with L-glutamine supplemented with 10% FBS and 1% penicillin/streptomycin
(ThermoFisher Scientific) overnight. Primary AML blast cells were seeded at a
density of 100,000 cells/well and treated with increasing concentrations of single
agent (6 concentration points; 10-fold dilution). After 96 h treatment, primary
AML blasts were separated from the MSC by manual pipetting. Cell Titer Glo was
used according to the manufacturer’s instructions and luminescence was measured.
IC50 concentrations were calculated, as described above. Plotly (Plotly, Inc.,
Montreal, Quebec) was used to generate a heatmap.
Cellular uptake and accumulation studies. Logarithmically growing cells (3 ×
106), were washed with PBS and seeded in 12-well plates with serum-free medium
containing a mixture of unlabeled and radioactively labeled cytarabine (total
concentration 1, 10, or 100 µM) or gemcitabine (total concentration 1 µM) and
were incubated for 5–120 min at 37 °C with 5% CO2. 3H-cytarabine (15 Ci mmol
−1) and 3H-gemcitabine (16.2 Ci mmol−1) were purchased from Moravek Bio-
chemicals (Brea, CA, USA). Cells were washed twice with ice-cold PBS; cell pellets
were solubilized in 400 µL 1 N NaOH and agitated (300 rpm) at room temperature
for 2 h. Then samples were neutralized with 200 µL 1M HCl; a 25 µL aliquot of
lysate was used to estimate protein concentration using a Pierce BCA protein assay
kit (Thermo Scientific). Total radioactivity was measured by a Tri-Carb 4810TR
liquid scintillation counter (Perkin-Elmer) after mixing the sample with 4 mL of
Emulsifier Safe (Perkin Elmer); the results were normalized to total protein content
as measured by a Pierce BCA protein assay kit. Three independent experiments
were performed in triplicate.
Total radioactivity was also detected in the nuclear cell fraction, for these
experiments 5 × 106 cells were treated with a mixture of unlabeled and radioactively
labeled cytarabine or gemcitabine (total concentration 1 µM) for 2 h, washed twice
with ice-cold PBS then resuspended in 500 µL 1× hypotonic buffer (20 mM
Tris–HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2) and incubated for 15 min on ice.
Next, 25 µL of detergent (10% NP4O, Thermo Scientific) was added, then samples
were vortexed for 10 s at highest setting followed by centrifugation for 10 min at
3000 rpm at 4 °C. The nuclear pellet was resuspended in 50 µL complete extract ion
buffer (cell extraction buffer [Life Technologies], protease inhibitor cocktail
[Calbiocehem], 1 mM PMSF) and incubated for 30 min on ice with vortexing at 10
min intervals then centrifuged for 30 min at 14,000×g at 4 °C. The supernatant
containing the nuclear fraction was transferred to a clean tube; 40 µL was used to
detect radioactivity using the liquid scintillation counter. A Pierce BCA protein
assay was performed on the cytoplasmic fraction of each sample and results were
normalized to total protein content. Three independent experiments were
performed in triplicate.
HPLC to detect compounds and metabolites. Logarithmically growing cells (3 ×
106), were washed and seeded in 12-well plates with serum-free medium containing
a mixture of unlabeled and radioactively labeled cytarabine or gemcitabine (total
concentration 1 µM) and were incubated for 2 h at 37 °C with 5% CO2. Cells were
washed twice in ice-cold PBS then resuspended in 300 µL of buffer containing 70%
methanol and 30% 15mM Tris (pH 7.4) and shaken (300 rpm) for 10 min at 4 °C.
After centrifugation, 50 µL of cell extract was removed for protein concentration
measurement using a Pierce BCA protein assay kit. Intracellular cytarabine,
gemcitabine, and phosphorylated metabolites were measured by HPLC. The fol-
lowing standards were used: Ara-C, cytidine 5′-monophosphate disodium salt
(Sigma), cytidine 5′-diphosphocholine sodium salt (Sigma), cytidine 5′-dipho-
sphate trisodium salt (Sigma), cytidine 5′-triphospahte disodium salt (Sigma),
gemcitabine hydrochloride (Sigma), gemcitabine monophosphate (Toronto
Research Chemicals), gemcitabine diphosphate trimethylamine salt (Toronto
Research Chemicals), gemcitabine triphosphate ditriethylamine (Toronto Research
Chemicals). All standards were prepared to a concentration of 1 mgmL−1 in water.
Analysis was carried out with a Hewlett Packard Series 1100 HPLC. Separation was
achieved on a PARTISIL SAX anion exchange HPLC column (Whatman 4.6 mm ×
250 mm × 10 µM particles) at room temperature. Mobile phase A is 0.5 mM
NH4H2PO4, and mobile phase B is 500 mM NH4H2PO4 pH 3.4. Flow rate is varied
from 0.5 to 1.0 mLmin−1 at a temperature of 40 °C. The gradient was modified in
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such a manner that it is held isocratically from 0 to 10 min at a flow rate of 0.5 mL
min−1. At 10 min the flow changes to 1.0 mLmin−1 and a linear gradient runs
from 0 to 100% B from 10.01 to 40 min. Fractions were collected directly into
scintillation vials at 1 min intervals using an Eldex Universal Fraction Collector.
The total run time was 70 min. After addition of Scintisafe 30% scintillation fluid
(Perkin Elmer), samples were vortexed and radioactivity was measured on a Tri-
Carb 4810TR liquid scintillation counter. Total radioactivity was expressed as
disintegrations per minute (DPMs) and normalized to protein concentration.
Three independent experiments were performed.
Silencing of ENT1 and OCTN1 expression. The on-target plus SMART pool
human SLC22A4 siRNA for OCTN1 silencing (Dharmacon, Inc./Horizon, Cam-
bridge, UK), and the Mission siRNAs targeting ENT1 or negative non-targeting
control (Sigma-Aldrich) were used in all experiments. MOLM-13 cells were
transfected with siRNA control, siRNA OCTN1 or siRNA ENT1 using Nucleo-
fector II and Nucleofector Kit C (Lonza) program X-001, according to the man-
ufacturer’s protocol. Briefly, MOLM-13 cells (3 × 106) were transfected with
200–500 nM siRNA for each sample; suppression of OCTN1 (Hs00268200_m1)
and ENT1 (Hs01085704_g1) was evaluated using a TaqMan qRT-PCR assay at 48
h post-transfection; expression levels were normalized to GAPDH
(Hs02758991_g1; VIC). Cytotoxicity studies were initiated in MOLM-13 cells 24 h
after transfection. Asynchronous cells were treated with PBS, 10 nM gemcitabine,
or 100 nM cytarabine for 16 h; then cells were harvested for cell cycle distribution
as described below.
Cell cycle distribution and induction of mitosis. Asynchronous cells were treated
with 5 or 50 nM cabazitaxel for up to 24 h; DMSO was the control agent. At
indicated time points (4, 8, 12, 16, 24 h) cells were collected and washed once with
0.1% EDTA (Ricca Chemical Company, Arlington, TX) in PBS then washed once
with PBS only. Next, cells were fixed with ice-cold 70% ethanol for 30 min on ice or
stored at −20 °C for up to 1 month. Cells were spun down at 450×g for 10 min and
stained with DAPI (DAPI final concentration 1 µg mL−1 [ThermoFisher Scien-
tific]) in 0.1% Triton-X [ThermoFisher Scientific]/PBS for 30 min at room tem-
perature and protected from light. The DNA content was determined using a BD
LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). The cell cycle dis-
tribution was analyzed using FlowJo v10.0.08 software (FlowJo, LLC, Ashland, OR).
For biparametric analysis of mitosis, cells were fixed with 16% paraformaldehyde
(Avantor, Center Valley, PA) in PBS at room temperature for 10 min, washed twice
with PBS then permeabilized with ice-cold 95% methanol (ThermoFisher Scien-
tific) and incubated at −20 °C. Cells were rehydrated in FACS buffer (PBS+ 4%
FBS) and stained with cyclin B1-APC (Cell Signaling Technology, Inc., Danvers,
MA) and phospho-histone H3-FITC (Cell Signaling Technology, Inc.). Two-color
flow cytometry was performed using a BD LSR II flow cytometer (BD Biosciences)
and the data was analyzed using FlowJo (FlowJo, LLC).
Binding assay. Binding of ruxolitinib and tofacitinib to purified JAK1, JAK2,
JAK3, and TYK2 kinases were performed using a commercially available KdELECT
assay (DiscoverRx, Fremont, CA), as previously described58. The binding constant
(Kd) was calculated with a standard dose-response curve using the Hill equation
(slope set to −1); curves were fitted using a non-linear least square fit with the
Levenberg–Marquardt algorithm.
Kinase assay. In vitro profiling of JAK1, JAK2, JAK2V617F, JAK3, and TYK2
kinase were performed at Reaction Biology Corporation59. Briefly, specific kinase/
substrate pairs were prepared in fresh base reaction buffer (20 mM HEPES at pH
7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4,
2 mM DTT, 1% DMSO). Compounds were delivered into the reaction and incu-
bated for 20 min. Next, 33P-ATP was delivered to the reaction mixture to initiate
the reaction and incubated for 2 h at room temperature. Reactions were spotted
onto P81 ion exchange paper and kinase activity was detected by filter-binding
method.
RNA isolation and qRT-PCR. RNA was isolated from cell lines using Trizol
(Invitrogen) chloroform (Sigma-Aldrich) extraction. cDNA was generated from 1
µg of RNA using the SuperScript IV First-Strand Synthesis System (Invitrogen)
according to the manufacturer’s instructions. PCR with reverse transcription was
performed using TaqMan master mix (Life Technologies) at 2× dilution; TaqMan
expression assays (Applied Biosystems) for OCTN1 (Hs00268200_m1; FAM),
ENT1 (Hs01085704_g1; FAM), STA5A (Hs00559643_m1; FAM) and GAPDH
(Hs02758991_g1; VIC) were used. A QuantStudio 3 system (Life Technologies)
was used to perform quantitative PCR. Analyses were performed in technical tri-
plicates using the delta Ct method.
RNA-seq library preparation. Gene expression profiles for JAK-STAT family
members were done utilizing RNA-seq data. RNA sequencing libraries were pre-
pared using 1 µg of RNA using TruSeq RNA Prep v2 kits according to the man-
ufacturer’s instructions (Illumina, Inc., San Diego, CA). Paired-end sequencing was
performed on an Illumina HiSeq2000 using TruSeq SBS v3 reagents kits according
to the manufacturer’s instructions, at the SJCRH Hartwell Center. To quantify the
expression level of each gene, we performed the following procedures: (1) for each
annotated exon in the RefSeq genes, we obtained the average coverage; (2) due to
the high variations of coverage across different exons for each gene, we used the
average coverage of the best covered exon as the expression level for each gene.
After we combine the expression for all 12 samples, we only retained those genes
whose expression level is at least 10 in at least one sample in order to exclude genes
that are unexpressed or poorly expression across all samples. For gene expression
comparisons, we obtained counts of the number of reads per gene and carried out
fragment per kilobase mapped (FPKM) normalization and a quantile normal-
ization was performed to adjust different sequencing depths for each sample.
Murine bone marrow transduction and transplantation. All animal studies were
performed in accordance with Animal Care and Use Programs under protocols
approved by the Institutional Animal Care and Use Committee at SJCRH or The
Ohio State University (OSU). We have complied with the relevant ethical con-
siderations for animal research overseen by this committee. Bone marrow from
4–6-week-old female C57BL/6 mice was harvested, lineage depleted (Lineage Cell
Depletion Kit, Miltenyi Biotec Inc., Auburn, CA) and cultured in the presence of
cytokines for 24 h prior to transduction on RetroNectin (Takara Bio Inc., Kyoto,
Japan). Ectopic envelope-pseudotyped retroviral vectors were produced and
replication-incompetent supernatant was made by transiently transfecting 293
T cells29,60. For primary bone marrow transplants, 0.1 × 106 single (GFP, mCherry)
or double-positive cells with 1 × 106 protected cells were injected intravenously via
tail vein on day 0. Recipient mice were conditioned with total body irradiation at a
dose of 1100 rad divided on days −1 and 0. For secondary-quaternary transplants,
2 × 106 bone marrow and splenic cells from moribund mice were isolated and
injected intravenously into recipient mice conditioned with 500 rad. Alternatively,
double-positive cells isolated from secondary transplants and were transduced with
a luciferase-BFP to generate CG/V617-Luc+ AMKL blasts; GFP/mCherry/BFP
triple-positive cells were purified by flow cytometry then injected into conditioned
tertiary or quaternary recipients.
Establishment of in vivo gemcitabine maximum tolerated dose. All animal
studies were performed in accordance with Animal Care and Use Programs under
protocols approved by the Institutional Animal Care and Use Committee at OSU.
We have complied with the relevant ethical considerations for animal research
overseen by this committee. Mice were housed in a barrier facility. Non-tumor
bearing Ly5.2 C57Bl/6 (BoyJ) mice were treated with 100, 120, or 140 mg kg−1
gemcitabine on an intermittent schedule every 3 days for 3 weeks; 3 or 6 mg kg−1
doses were used to evaluate daily for 5 days schedule. All doses were administered
by intraperitoneal injection; tolerability was assessed by daily weights and obser-
vation of changes in body condition.
In vivo efficacy studies in murine models of AML. All animal studies were
performed in accordance with Animal Care and Use Programs under protocols
approved by the Institutional Animal Care and Use Committee at OSU. We have
complied with the relevant ethical considerations for animal research overseen by
this committee. Mice were housed in a barrier facility. For cell line xenografts, NSG
mice were procured from the OSU Comprehensive Cancer Center Target Vali-
dation Shared Resource. To label CHRF288-11 cells, lentivirus encoding firefly
luciferase (LUC) and YFP (CL20SF2-Luc2AYFP with VSV-G envelope; SJCRH
Vector Core) was used. Briefly, CHRF288-11 cells were transduced by spinfection
using retronectin coated plates and 10 µL of concentrated viral supernatant
obtained from the SJCRH Vector Core. Following transduction, cells were single
cell sorted into each well of a 96-well plate by flow cytometry, individual clones
were expanded, then evaluated in vivo for engraftment. For efficacy studies, mice
were injected intravenously via tail vein with 5 × 106 CHRF288-11-LUC/YFP+ or
ML-2-LUC/YFP+ cells; engraftment was monitored by noninvasive imaging per-
formed once weekly starting on day 6 or 7 after injection. The Luciferase substrate
D-luciferin firefly potassium salt (Gold Biotechnology, Inc., St. Louis, MO, USA)
was administered by intraperitoneal injection at a dose of 150 mg/kg. Mice were
anesthetized by 1.5–2.5% isoflurane (Baxter, Deerfield, IL, USA) inhalation; bio-
luminescence was determined 5 min later using a Xenogen IVIS-200 imaging
system (Perkin Elmer). Total body bioluminescence was quantified for the body
area that included each mouse in its entirety (Living Image 4.3.1, Perkin Elmer).
For AMKL PDX, 1 × 106 cells whole bone marrow and spleen cells isolated from an
individual primary transplant recipient were injected intravenously into sublethally
irradiated (200 rad) NSG-SGM3 female mice that were 8–12 weeks old for
expansion. For efficacy studies, 1 × 106 cells whole bone marrow and spleen cells
isolated from an individual secondary transplant recipient were injected intrave-
nously into sublethally irradiated (200 rad) NSG-SGM3 female mice that were
8–12 weeks old. Transplant studies used whole bone marrow and spleen cells from
an individual MllPTD/wt:Flt3ITD/ITD double knock-in (dKI) mouse or individual
CG-V617F-Luc+ tertiary transplant recipient that had been stored in liquid
nitrogen. After thawing, 2 × 106 cells were injected intravenously into sublethally
irradiated (500 rad) Ly5.1+ syngeneic female mice that were 8–12 weeks old. Due
to the severely enlarged spleens (weight >1 g) in CG-V617F-Luc transplant reci-
pients imaging is discontinued after day 45 and tumor burden is monitored by
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peripheral blood for the remainder of the study. To establish the PDX model, a
single vial of patient cells was thawed and engrafted in primary recipients then
further expanded in secondary recipients; whole bone marrow and spleen cells
were stored in liquid nitrogen. On day −1, 8–12-week-old triple transgenic NSG-
SGM3 mice (The Jackson Laboratory; Bar Harbor, ME, USA) expressing human
IL-3, GM-CSF, and SCF were sublethally irradiated (200 rad) with one dose of total
body irradiation. On day 0, 2 × 106 cells were injected intravenously via tail vein
into tertiary recipients. Leukemia progression was monitored by white blood cell
(WBC) count analysis and/or detection of Ly5.2+ cells, GFP/mCherry-double
positive, or human CD45 positive cells in peripheral blood by flow cytometry
weekly. All mice were observed daily and humanely euthanized when showing
signs of progressive disease including, hind limb paralysis, weight loss more than
15%, and lethargy.
To evaluate anti-leukemic activity NSG/NSG-SGM3 mice and dKI AML
primary recipients were randomly assigned upon detection of significant tumor
burden, based on imaging data or peripheral blood analysis, to receive vehicle,
cytarabine or gemcitabine 50 mg kg−1, or cabazitaxel 5 mg kg−1 once every 4 days
for 3 weeks; some mice were administered two cycles of dosing regimen with
1 week off between cycles as indicated. CG-V617-Luc+ quaternary recipients and
dKI secondary recipients were administered 50 or 100 mg kg−1 cytarabine once
daily for 5 days, 3 mg kg−1 gemcitabine once daily for 5 days, or 120 mg kg−1
gemcitabine once every 3 days for 3 weeks; some mice were administered two
cycles of dosing regimen with 2 weeks off between daily schedules and 1 week off
for the intermittent schedule. Cytarabine and gemcitabine were formulated in PBS;
cabazitaxel was made fresh daily, formulated in 5% ethanol/5% Tween-80/5%
glucose water; all treatments were administered by intraperitoneal injection.
Ruxolitinib was reconstituted in 0.5% methylcellulose with overnight end-over-end
mixing and administered by oral gavage twice daily for 5 days for 4 weeks.
Treatment started on day 10 (CHRF288-11-LUC/YFP+) or 17 (ML-2-LUC/YFP+)
when significant bone marrow engraftment was observed, as determined by
imaging analysis. Similarly, treatment started on day 13 for mice primary recipients
with MllPTD/wt:Flt3ITD/ITD dKI AML or day 7 for secondary recipients, and day 17
or 20 for CG-V617-Luc+ AMKL after first observation of >2% Ly5.2+ or GFP/
mCherry-double+ cells in peripheral blood or spleen. Treatment started on day 11
for the AMKL PDX after first observation of >2% human CD45 cells in
peripheral blood.
Bone marrow and splenocytes were isolated from mice transplanted with dKI
AML and CG-V617 AMKL. Following red blood cells lysis, dKI AML leukemic
blasts from vehicle treated mice were evaluated for accumulation of cytarabine and
gemcitabine using the uptake assay described above. CG-V617 AMKL leukemic
blasts from treatment-naive tertiary transplants were subjected to red blood cell
lysis then subjected to cell viability assay using increasing concentrations of
ruxolitinib as described above.
Pharmacokinetics of ruxolitinib. Animal studies were performed under protocols
approved by the Institutional Animal Care and Use Committee at OSU. Single dose
pharmacokinetic studies were conducted in 8–12-week-old female and male NSG
and BoyJ mice to determine a ruxolitinib dose that produces human equivalent
exposure. For these studies, 60 mg kg−1 of ruxolitinib was administered by oral
gavage in 0.5% methylcellulose. Serial blood collection was performed from 15 min
up to 240 min after dose administration. Total ruxolitinib concentrations in plasma
were measured using a modification of previously published methods61. Quanti-
tation was carried out by liquid chromatography-tandem mass spectrometry with a
Vanquish UHPLC system and a TSQ Quantum mass spectrometer (ThermoFisher
Scientific); separation was achieved in 5 min using an Accucore Vanquish C18
column and the system was controlled using Thermo Trace Finder General Quan
software.
Immunoblot analysis. For protein expression of p-STAT5A and total-STAT5A,
cells were lysed and whole cell lysates were prepared using radio-
immunoprecipitation assay buffer (Sigma-Aldrich) supplemented with protease
and phosphatase inhibitors. Total cell lysate (20 µg) was separated by SDS-
polyacrylamide gel electrophoresis according to the manufacturer’s instructions
(Life Technologies) and transferred to PVDF membranes. Western blot analysis
was then performed using p-STAT5A (1:1000, Cell Signaling Technology, Danvers,
MA) and t-STAT5A (1:1000, Cell Signaling Technology); secondary α-rabbit or α-
mouse antibodies (1:2000, Jackson ImmunoResearch, West Grove, PA) were used
and proteins were visualized using the SignalFire ECL Reagent (Cell Signaling
Technology) on an Odyssey Fc Imaging System (LI-COR, Lincoln, NE). GAPDH
(Santa Cruz Biotechnology, Inc., Dallas, TX) was used a loading control; immu-
noblots were performed a minimum of three times on samples collected from
different experiments. Uncropped and unprocessed blots are provided in the Data
Source file.
Statistical analysis. Prism software (GraphPad Software) was used for statistical
analyses. Kaplan–Meier analysis of animal survival and statistical significance of
data was determined by log rank test; P < 0.05 was considered statistically sig-
nificant. All other statistical tests performed are indicated in corresponding text or
figure legend; P < 0.05 was considered statistically significant. A linear regression
analysis was performed to evaluate a goodness of fit and determine the Pearson
correlation between STAT5A expression and ruxolitinib sensitivity.
Data availability
The RNA-seq data generated and analyzed in this study are available at the Gene
Expression Omnibus (GEO) repository of the National Center for Biotechnology
Information under accession code GSE126489. The authors declare that all data
generated from this study are included in this publication and its Supplementary
Information, Source Data file (Figs. 2–7; Supplementary Figs. 1, 3, 5, 7, 9, 13, 15, 16), or
available from the corresponding author on request.
Code availability
High-throughput screening data was analyzed using our in-house Robust Interpretation
of Screening Experiments (RISE) application written in Pipeline Pilot (Accelrys, v8.5)
and the R program (R Development Core Team). The Pipeline Pilot protocol (exported
as a Pipeline Pilot formatted xml file), including the embedded R code, are reported
in Supplementary Software.
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